As part of our Masters in Vaccinology, we had the privilege to participate in an intensive two-week immersion at GSK—a leading biopharmaceutical company committed to the prevention and treatment of disease through specialty medicines, vaccines, and general medicines. GSK’s strategic focus on the immune system and advanced technologies, along with targeted investments in core therapeutic areas, exemplifies the forefront of scientific innovation and global health impact.
Throughout the program, we explored the comprehensive vaccine development continuum, encompassing foundational discovery science, preclinical evaluation, clinical development, regulatory strategy, manufacturing quality assurance, pharmacovigilance, and market access. Each module provided detailed scientific perspectives that highlighted the complexity and rigor involved in translating biological hypotheses into safe, effective, and accessible vaccines.
Our learning deepened around novel vaccine technologies, including the pivotal roles of adjuvants, delivery platforms, and the bioethical considerations integral to human research. The meticulous processes of clinical trials reinforced the necessity for robust safety and efficacy assessments, while the regulatory frameworks illuminated the dynamic interplay between science, policy, and public trust.
Modules on pharmacovigilance and quality assurance emphasized the continuous vigilance essential post-approval to safeguard vaccine safety across diverse populations, underscoring a steadfast commitment to patient well-being and global health security. Discussions on manufacturing scale-up and supply chain logistics further provided practical insights into the challenges of delivering vaccines worldwide—effectively bridging scientific breakthroughs with public health outcomes.
The program culminated in a rigorous presentation round, during which students synthesized their knowledge through innovative problem-solving and strategic communication exercises. This collaborative innovation challenge was particularly impactful, reflecting the diverse expertise within our cohort and underscoring the multidisciplinary nature of vaccine science within industry contexts.
Overall, this immersion offered an unparalleled opportunity to observe firsthand the sophisticated scientific, regulatory, and operational frameworks that underpin vaccine development at industrial scale. It fostered a profound appreciation for the collaborative and iterative nature of vaccinology and reinforced our commitment to contribute meaningfully to this critical field. The knowledge and insights gained have broadened our scientific horizons and equipped us with the practical skills necessary to navigate and shape the future landscape of vaccine innovation.
We extend our deepest gratitude to the entire GSK LIVE team for their unwavering support, patience, and encouragement throughout the two-week program. We are especially grateful to Dr. Norbert De Clercq, Dr. Valérie Massem, Dr. Laurence Beyst, and Dr. Elisa Marchetti for their exemplary leadership and dedication, which were instrumental in making this immersive experience both possible and profoundly impactful. Their commitment to fostering a collaborative and inspiring learning environment made this journey truly memorable and enriching for all participants.
Master LIVE M1 visit the GSK site in Wavre
As part of our Masters in Vaccinology, we had the privilege to participate in an intensive two-week immersion at GSK—a leading biopharmaceutical company committed to the prevention and treatment of disease through specialty medicines, vaccines, and general medicines. GSK’s strategic focus on the immune system and advanced technologies, along with targeted investments in core therapeutic areas, exemplifies the forefront of scientific innovation and global health impact.
Throughout the program, we explored the comprehensive vaccine development continuum, encompassing foundational discovery science, preclinical evaluation, clinical development, regulatory strategy, manufacturing quality assurance, pharmacovigilance, and market access. Each module provided detailed scientific perspectives that highlighted the complexity and rigor involved in translating biological hypotheses into safe, effective, and accessible vaccines.
Our learning deepened around novel vaccine technologies, including the pivotal roles of adjuvants, delivery platforms, and the bioethical considerations integral to human research. The meticulous processes of clinical trials reinforced the necessity for robust safety and efficacy assessments, while the regulatory frameworks illuminated the dynamic interplay between science, policy, and public trust.
Modules on pharmacovigilance and quality assurance emphasized the continuous vigilance essential post-approval to safeguard vaccine safety across diverse populations, underscoring a steadfast commitment to patient well-being and global health security. Discussions on manufacturing scale-up and supply chain logistics further provided practical insights into the challenges of delivering vaccines worldwide—effectively bridging scientific breakthroughs with public health outcomes.
The program culminated in a rigorous presentation round, during which students synthesized their knowledge through innovative problem-solving and strategic communication exercises. This collaborative innovation challenge was particularly impactful, reflecting the diverse expertise within our cohort and underscoring the multidisciplinary nature of vaccine science within industry contexts.
Overall, this immersion offered an unparalleled opportunity to observe firsthand the sophisticated scientific, regulatory, and operational frameworks that underpin vaccine development at industrial scale. It fostered a profound appreciation for the collaborative and iterative nature of vaccinology and reinforced our commitment to contribute meaningfully to this critical field. The knowledge and insights gained have broadened our scientific horizons and equipped us with the practical skills necessary to navigate and shape the future landscape of vaccine innovation.
We extend our deepest gratitude to the entire GSK LIVE team for their unwavering support, patience, and encouragement throughout the two-week program. We are especially grateful to Dr. Norbert De Clercq, Dr. Valérie Massem, Dr. Laurence Beyst, and Dr. Elisa Marchetti for their exemplary leadership and dedication, which were instrumental in making this immersive experience both possible and profoundly impactful. Their commitment to fostering a collaborative and inspiring learning environment made this journey truly memorable and enriching for all participants.
2025.06.09 – Belkaid Prom’
Menu
Archives